Investegate |Active Biotech Announcements | Active Biotech: Active Biotech Interim report January
Investegate announcements from Active Biotech, Active Biotech Interim report January - September 2021
Source: investegate.co.uk
Page 8 - Active Biotech News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Active Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Active Biotech Today - Breaking & Trending Today
Investegate |Active Biotech Announcements | Active Biotech: New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
Investegate announcements from Active Biotech, New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
Source: investegate.co.uk
Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)
Lund, October 20, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox
Source: finanznachrichten.de
Investegate |Active Biotech Announcements | Active Biotech: Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US
Investegate announcements from Active Biotech, Active Biotech: Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US
Source: investegate.co.uk
Active Biotech: Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US
Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. Ten patients have been
Source: finanznachrichten.de